Randomized phase II trial designs with biomarkers

Boris Freidlin, Lisa M. McShane, Mei-Yin Polley, Edward L. Korn

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

Efficient development of targeted therapies that may only benefit a fraction of patients requires clinical trial designs that use biomarkers to identify sensitive subpopulations. Various randomized phase III trial designs have been proposed for definitive evaluation of new targeted treatments and their associated biomarkers (eg, enrichment designs and biomarker-stratified designs). Before proceeding to phase III, randomized phase II trials are often used to decide whether the new therapy warrants phase III testing. In the presence of a putative biomarker, the phase II trial should also provide information as to what type of biomarker phase III trial is appropriate. A randomized phase II biomarker trial design is proposed, which, after completion, recommends the type of phase III trial to be used for the definitive testing of the therapy and the biomarker. The recommendations include the possibility of proceeding to a randomized phase III of the new therapy with or without using the biomarker and also the possibility of not testing the new therapy further. Evaluations of the proposed trial design using simulations and published data demonstrate that it works well in providing recommendations for phase III trial design.

Original languageEnglish (US)
Pages (from-to)3304-3309
Number of pages6
JournalJournal of Clinical Oncology
Volume30
Issue number26
DOIs
StatePublished - Sep 10 2012
Externally publishedYes

Fingerprint

Biomarkers
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized phase II trial designs with biomarkers. / Freidlin, Boris; McShane, Lisa M.; Polley, Mei-Yin; Korn, Edward L.

In: Journal of Clinical Oncology, Vol. 30, No. 26, 10.09.2012, p. 3304-3309.

Research output: Contribution to journalReview article

Freidlin, Boris ; McShane, Lisa M. ; Polley, Mei-Yin ; Korn, Edward L. / Randomized phase II trial designs with biomarkers. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 26. pp. 3304-3309.
@article{33d53b72a2b240718e794075c36b0c91,
title = "Randomized phase II trial designs with biomarkers",
abstract = "Efficient development of targeted therapies that may only benefit a fraction of patients requires clinical trial designs that use biomarkers to identify sensitive subpopulations. Various randomized phase III trial designs have been proposed for definitive evaluation of new targeted treatments and their associated biomarkers (eg, enrichment designs and biomarker-stratified designs). Before proceeding to phase III, randomized phase II trials are often used to decide whether the new therapy warrants phase III testing. In the presence of a putative biomarker, the phase II trial should also provide information as to what type of biomarker phase III trial is appropriate. A randomized phase II biomarker trial design is proposed, which, after completion, recommends the type of phase III trial to be used for the definitive testing of the therapy and the biomarker. The recommendations include the possibility of proceeding to a randomized phase III of the new therapy with or without using the biomarker and also the possibility of not testing the new therapy further. Evaluations of the proposed trial design using simulations and published data demonstrate that it works well in providing recommendations for phase III trial design.",
author = "Boris Freidlin and McShane, {Lisa M.} and Mei-Yin Polley and Korn, {Edward L.}",
year = "2012",
month = "9",
day = "10",
doi = "10.1200/JCO.2012.43.3946",
language = "English (US)",
volume = "30",
pages = "3304--3309",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

TY - JOUR

T1 - Randomized phase II trial designs with biomarkers

AU - Freidlin, Boris

AU - McShane, Lisa M.

AU - Polley, Mei-Yin

AU - Korn, Edward L.

PY - 2012/9/10

Y1 - 2012/9/10

N2 - Efficient development of targeted therapies that may only benefit a fraction of patients requires clinical trial designs that use biomarkers to identify sensitive subpopulations. Various randomized phase III trial designs have been proposed for definitive evaluation of new targeted treatments and their associated biomarkers (eg, enrichment designs and biomarker-stratified designs). Before proceeding to phase III, randomized phase II trials are often used to decide whether the new therapy warrants phase III testing. In the presence of a putative biomarker, the phase II trial should also provide information as to what type of biomarker phase III trial is appropriate. A randomized phase II biomarker trial design is proposed, which, after completion, recommends the type of phase III trial to be used for the definitive testing of the therapy and the biomarker. The recommendations include the possibility of proceeding to a randomized phase III of the new therapy with or without using the biomarker and also the possibility of not testing the new therapy further. Evaluations of the proposed trial design using simulations and published data demonstrate that it works well in providing recommendations for phase III trial design.

AB - Efficient development of targeted therapies that may only benefit a fraction of patients requires clinical trial designs that use biomarkers to identify sensitive subpopulations. Various randomized phase III trial designs have been proposed for definitive evaluation of new targeted treatments and their associated biomarkers (eg, enrichment designs and biomarker-stratified designs). Before proceeding to phase III, randomized phase II trials are often used to decide whether the new therapy warrants phase III testing. In the presence of a putative biomarker, the phase II trial should also provide information as to what type of biomarker phase III trial is appropriate. A randomized phase II biomarker trial design is proposed, which, after completion, recommends the type of phase III trial to be used for the definitive testing of the therapy and the biomarker. The recommendations include the possibility of proceeding to a randomized phase III of the new therapy with or without using the biomarker and also the possibility of not testing the new therapy further. Evaluations of the proposed trial design using simulations and published data demonstrate that it works well in providing recommendations for phase III trial design.

UR - http://www.scopus.com/inward/record.url?scp=84866615115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866615115&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.43.3946

DO - 10.1200/JCO.2012.43.3946

M3 - Review article

C2 - 22869885

AN - SCOPUS:84866615115

VL - 30

SP - 3304

EP - 3309

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 26

ER -